Association of Systemic Inflammation Indices With Mortality in Coronary Atherosclerosis Patients With and Without

Weiren Yan1, Bingqian Zhang1, Xiaoyan Zhang2

  • 1Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, China, dlmedu.edu.cn.

Mediators of Inflammation
|January 12, 2026
PubMed

Insights

Inflammation markers, systemic immune inflammatory index (SII) and systemic inflammatory response index (SIRI), predict mortality in coronary heart disease (CHD) patients, regardless of standard modifiable risk factors (SMuRFs). Higher SII and SIRI levels are linked to increased all-cause mortality in both SMuRF-present and SMuRF-less CHD groups.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Public Health Epidemiology

Background:

  • Standard modifiable risk factors (SMuRFs) are key drivers of coronary atherosclerosis.
  • A subset of individuals develop coronary atherosclerosis without identifiable SMuRFs, suggesting alternative etiological pathways.
  • Inflammation is recognized as a significant contributor to atherosclerosis development and progression.

Purpose of the Study:

  • To investigate the association between novel inflammatory markers, systemic immune inflammatory index (SII) and systemic inflammatory response index (SIRI), and mortality in coronary heart disease (CHD) patients.
  • To examine these associations separately in patients with and without SMuRFs.
  • To explore the role of inflammation as a potential driver of poor prognosis in SMuRF-less CHD patients.

Main Methods:

  • Analysis of 1708 CHD participants from the National Health and Nutrition Examination Survey (NHANES) (1999-2018).
  • Categorization of participants into '≥1 SMuRF' and 'SMuRF-less' groups based on questionnaires and serologic testing.
  • Assessment of mortality risk using multivariate weighted Cox regression and restricted cubic spline (RCS) analysis for SII and SIRI, stratified by SMuRF status.

Main Results:

  • In patients with ≥1 SMuRF, higher quartiles of SII and SIRI were significantly associated with increased all-cause and cardiovascular mortality.
  • In SMuRF-less patients, elevated SII and SIRI levels were significantly linked to higher all-cause mortality, with SIRI also showing a significant association with cardiovascular mortality.
  • RCS analysis revealed a positive linear trend between higher SII/SIRI levels and all-cause mortality in both SMuRF groups, and cardiovascular mortality in the SMuRF-present group.

Conclusions:

  • SII and SIRI are independently associated with all-cause mortality in CHD patients, irrespective of SMuRF status.
  • Inflammation, as indicated by SII and SIRI, may play a crucial role in the adverse outcomes of patients with CHD, particularly those lacking traditional risk factors.
  • Further prospective studies are warranted to confirm these findings and elucidate the underlying mechanisms.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
868
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
204
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
314
Inflammation01:38

Inflammation

Overview
61.5K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
277